MURALI CHINTAGUMPALA to DNA Methylation
This is a "connection" page, showing publications MURALI CHINTAGUMPALA has written about DNA Methylation.
Connection Strength
0.784
-
Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. J Clin Oncol. 2021 03 01; 39(7):807-821.
Score: 0.115
-
Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). J Clin Oncol. 2021 03 01; 39(7):822-835.
Score: 0.115
-
Pilot study of DNA methylation-derived neutrophil-to-lymphocyte ratio and survival in pediatric medulloblastoma. Cancer Epidemiol. 2019 04; 59:71-74.
Score: 0.101
-
Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol. 2018 06; 19(6):785-798.
Score: 0.096
-
DNA methylation of a novel PAK4 locus influences ototoxicity susceptibility following cisplatin and radiation therapy for pediatric embryonal tumors. Neuro Oncol. 2017 Oct 01; 19(10):1372-1379.
Score: 0.092
-
Exploratory analysis of ERCC2 DNA methylation in survival among pediatric medulloblastoma patients. Cancer Epidemiol. 2016 10; 44:161-166.
Score: 0.085
-
Satellite DNA hypomethylation in karyotyped Wilms tumors. Cancer Genet Cytogenet. 2003 Mar; 141(2):97-105.
Score: 0.033
-
Epigenetic Alterations of Repeated Relapses in Patient-matched Childhood Ependymomas. Nat Commun. 2022 11 05; 13(1):6689.
Score: 0.033
-
Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene. 2002 Sep 26; 21(43):6694-702.
Score: 0.032
-
Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. Clin Cancer Res. 2021 05 15; 27(10):2879-2889.
Score: 0.029
-
Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials. Acta Neuropathol. 2020 02; 139(2):259-271.
Score: 0.027
-
Germline GPR161 Mutations Predispose to Pediatric Medulloblastoma. J Clin Oncol. 2020 01 01; 38(1):43-50.
Score: 0.026